Povetacicept
Vertex Pharmaceuticals (VRTX)
Decision dateNov 30, 2026
15 days away
Marketer take
Would add another entrant to a fast-growing IgAN market that already includes Trutakna, raising the bar for nephrologist differentiation messaging.
- Sponsor company
- Vertex Pharmaceuticals (VRTX)
- Indication
- IgA nephropathy (accelerated approval)
- Therapeutic area
- Nephrology
- Event
- PDUFA target action date
- Date
- Nov 30, 2026
- Status
- Upcoming
- Source
- SEC filing
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?